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Summary
Background.— Peripheral arterial disease (PAD) is a marker of increased risk of cardiovascular
events and of poor prognosis in patients with coronary artery disease (CAD). The prevalence
of unknown PAD among patients with CAD varies between studies according to the mode of
diagnosis.
Aims.— To evaluate the prevalence of unknown PAD, diagnosed using the ankle-brachial index
(ABI), in patients from the IPSILON study with a CAD diagnosis; to assess the proﬁle of these
patients; and to determine predictors of PAD.Predictors Methods.— IPSILON was an observational, cross-sectional study. General practitioners mea-
sured ABI in 5679 consecutive adults aged 55 years or over with signs or symptoms suggestive
of PAD (21.3%), a history of an atherothrombotic event (42.1%) or two or more cardiovascular
risk factors (36.6%). This analysis focuses on the subgroup of patients with CAD and no other
known overt atherothrombotic disease.
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nariens. L’Aomi était asymptomatique dans plus de la moitié des cas. Le dépistage de l’Aomi
permettra d’identiﬁer une sous-population à risque cardiovasculaire particulièrement élevé.
Une prise en charge thérapeutique spéciﬁque pourrait améliorer le pronostic de ces patients.
© 2009 Elsevier Masson SAS. Tous droits réservés.
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tbbreviations
BI Ankle-brachial index
AD Coronary artery disease
I Conﬁdence interval
DL High-density lipoprotein
DL Low-density lipoprotein
AD Peripheral arterial disease
BP Systolic blood pressure
ackground
ardiovascular diseases are the leading causes of death in
ndustrialized countries. Prevention of cardiovascular dis-
ases in clinical practice usually focuses on risk factor
anagement of coronary heart disease, stroke or transient
schaemic attack. PAD remains too often ignored, although
t has the same underlying cause as cardiovascular dis-
ase and is a strong predictor of cardiovascular events
nd mortality, even when asymptomatic [1—5]. The ratio
(
i
1
w
ietween symptomatic and asymptomatic patients varies
rom 1:1 to 1:6 [4], meaning that a huge number of patients
resent with a high level of risk but without any symp-
oms. The PARTNERS study [6] emphasized how often PAD
s ignored by patients and physicians in the USA. This
s also true in France, as shown in the ATTEST study
7].
CAD is the most prevalent manifestation of cardiovas-
ular disease and is associated with high mortality and
orbidity rates. With CAD, as with other atherosclerotic
rterial diseases, the cardiovascular event rate is ampliﬁed
n cases of multiple and/or overlapping locations. Patients
ith polyvascular disease account for over 20% of vascular
atients [8,9]. In patients with established atheroscle-
otic arterial disease from the REACH Registry [10], the
ne-year rate of cardiovascular death/myocardial infarc-
ion/stroke/hospitalization for atherothrombotic event(s)
transient ischaemic attack, unstable angina or worsen-S. Kownator et al.
Results.— A total of 1340 patients presented with isolated CAD. PAD (ABI < 0.90) was diagnosed
in 26.6% of these patients; 16.2% were asymptomatic. Older age, symptoms suggestive of PAD
and cardiovascular risk factors were found to be independent predictors of PAD in multivariable
analysis.
Conclusion.— Over 26% of patients with CAD present with unknown PAD, as diagnosed using
ABI measurement. More than half of these patients are asymptomatic. Screening for PAD in
patients with CAD will allow detection of a subpopulation at particularly high cardiovascular
risk. An aggressive medical treatment strategy could help to improve their outcome.
© 2009 Elsevier Masson SAS. All rights reserved.
Résumé
Justiﬁcation.— L’artériopathie oblitérante des membres inférieurs (Aomi) est un indicateur
connu de risque accru d’événements cardiovasculaires et un marqueur de mauvais pronostic
chez les patients coronariens. La prévalence des Aomi méconnues chez les coronariens varie
selon la méthode diagnostique employée dans les différentes études.
Objectifs.— Évaluer la prévalence de l’Aomi méconnue diagnostiquée par mesure de l’index
de pression systolique (IPS) chez les patients coronariens de l’étude Ipsilon ; décrire le proﬁl de
ces patients ; et déterminer les facteurs prédictifs d’Aomi chez ces patients.
Méthodes.— Ipsilon était une étude observationnelle et transversale. L’IPS a été mesuré par des
médecins généralistes chez 5679 adultes consécutifs, d’âge supérieur ou égale à 55 ans : 21,3 %
avec signes cliniques évocateurs d’Aomi, 42,1 % avec antécédents de manifestation athéroma-
teuse, et 36,6 % avec au moins deux facteurs de risque cardiovasculaire associés. La présente
analyse a été menée dans le sous-groupe de patients coronariens sans aucune autre atteinte
connue de maladie athéromateuse.
Résultats.— Mille trois cent quarante patients présentaient une maladie coronarienne isolée.
Une Aomi (déﬁnie par un IPS inférieur à 0,90) a été diagnostiquée chez 26,6 % d’entre eux ;
16,2 % étaient asymptomatiques. En analyse multivariée, l’âge élevé, la présence de tout symp-
tôme évocateur d’Aomi et celle de facteurs de risque cardiovasculaire étaient des facteurs
indépendants associés à l’Aomi.
Conclusion.— La mesure de l’IPS a permis de détecter une Aomi chez 26,6 % des patients coro-ng of PAD) was 13.0% for patients with isolated CAD,
7.4% for patients with isolated PAD and 23.1% for patients
ith CAD plus PAD. This rate was even higher (26.3%)
n cases of CAD plus PAD plus cerebrovascular disease.
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Table 1 Main characteristics of patients with coro-
nary artery disease and no other known location of
atherothrombotic disease.
Characteristic Patients (n = 1340)
Mean age (S.D.), years 70.9 (8.8)
Men, n (%) 957 (71.4)
Mean body mass index (S.D.),
kg/m2
27.5 (4.3)
Cardiovascular risk factors, n (%)
Hypercholesterolaemia 1023 (76.3)
Hypertension 1021 (76.2)
Diabetes 424 (31.6)
Smoking (current/cessation
≤ 1 year)
209 (15.6)
None 78 (5.8)
Signs/symptoms of PAD, n (%)
Any leg pain while walking 405 (30.2)
Intermittent claudication 129 (9.6)
Pulseless dorsalis pedis/posterior
tibial artery
321 (24.0)
None 631 (47.1)
Cardiovascular history, n (%)
Angina pectoris 997 (74.4)
Myocardial infarction 597 (44.6)
Coronary artery bypass graft or
angioplasty
674 (50.3)
Abdominal aortic aneurysm 37 (2.8)
Renovascular hypertension (renal
artery stenosis)
20 (1.5)
CAD: coronary artery disease; PAD: peripheral arterial disease;
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tPrevalence of unknown PAD in CAD patients
In the PATHOS study, PAD was found in one third of
patients hospitalized for acute coronary or cerebrovas-
cular events and was a predictor of one-year fatal
and non-fatal cardiovascular events [11]. Other studies
showed that PAD increases the mortality rate in cases
of acute CAD [12,13], including a long-term evaluation
[14].
Considering the increased level of risk in patients pre-
senting with both CAD and PAD, and the frequency with
which PAD is ignored, we sought to determine the inci-
dence of unknown PAD in a cohort of patients with CAD.
The IPSILON study was carried out to evaluate the cur-
rent prevalence and predictors of PAD using the ABI in
5679 patients considered to be at high risk in primary care
[15]. This study included patients presenting with leg pain,
history of cardiovascular disease (CAD, cerebrovascular dis-
ease or PAD) or two or more conventional risk factors. Our
current investigation examines the prevalence of unknown
PAD among patients from the IPSILON study with a CAD
diagnosis.
Methods
IPSILON was a cross-sectional study. General practitioners
selected randomly from a national database were invited
to participate. Those who agreed received speciﬁc training
in the measurement of ABI under standardized conditions.
Training was carried out by experienced angiologists and
cardiologists in dedicated workshops.
Patients
General practitioners recruited the ﬁrst ﬁve consecutive
patients aged 55 years or over into the IPSILON study if they
were considered to be at high risk of PAD, irrespective of
the reason for seeing the general practitioner. Three clini-
cal, mutually exclusive, high-risk subgroups were predeﬁned
as follows:
• Group 1 had one or more signs or symptoms suggestive of
PAD (ﬁrst evidence of intermittent claudication, atypical
pain in a leg muscle [calf, thigh, or buttock] while walk-
ing, pulseless lower limb artery [dorsalis pedis, posterior
tibial, popliteal or femoral], iliac or femoral bruits and/or
lower limb ulcer or gangrene);
• Group 2 (secondary prevention) had a history of at
least one atherothrombotic event (myocardial infarction
[Q wave or non-Q wave], angina pectoris [stable or
unstable], ischaemic stroke, previously established symp-
tomatic PAD [Leriche-Fontaine stage II or higher] and/or
carotid, coronary or lower limb artery revascularization
[bypass graft or angioplasty]);
• Group 3 (primary prevention) had two or more cardiovas-
cular risk factors (history of smoking, hypercholestero-
laemia, diabetes and/or hypertension) and no history of
an atherothrombotic event.For the present analysis, we studied patients with
isolated CAD from Group 2. Isolated CAD was deﬁned as a his-
tory of myocardial infarction (Qwave or non-Qwave), angina
pectoris (stable or unstable) or coronary revascularization
1
c
o
t
tS.D.: standard deviation.
bypass graft or angioplasty), without cerebrovascular dis-
ase or a known history of PAD.
ata
atients’ demographic characteristics, body weight and
eight, signs or symptoms suggestive of PAD and cardio-
ascular medical and surgical histories were determined
y physical examination, questioning and from medical
ecords. Smoking history was established in patients cur-
ently or formerly (cessation ≤ 1 year) smoking at least one
igarette per day. History of hypercholesterolaemia was
eﬁned as a fasting LDL cholesterol concentration of greater
han or equal to 130mg/dL (3.4mmol/L) on two occasions
ithin the past year. The most recent concentrations of
otal, LDL and HDL cholesterol were also retrieved. Dia-
etes was deﬁned, regardless of whether it was type 1 or
ype 2, as a fasting glycaemia of greater than or equal to
26mg/dL on two occasions and/or use of diabetes medi-
ation. Hypertension was deﬁned as an SBP of greater than
r equal to 140mmHg, a diastolic blood pressure of greater
han or equal to 90mmHg on two occasions and/or use of
reatment.
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Table 2 Prevalence of unknown peripheral arterial disease (ankle-brachial index < 0.9) in patients with coronary artery
disease, according to their characteristics: univariate analysis (n = 357).
Patient characteristic Prevalence of PAD, n (%) p
Demography
Sex Men 263 (27.5) 0.272
Women 94 (24.5)
Age (years) 55—63 68 (21.5) 0.011
64—73 119 (25.5)
≥ 74 170 (30.5)
Body mass index (kg/m2) < 18.5 0 (0) 0.459
18.5—< 25 95 (25.9)
25—< 30 170 (26.0)
≥ 30 90 (29.0)
Sign or symptom suggestive of PAD
Any leg pain while walking Yes 175 (43.2) < 0.001
No 182 (19.5)
Intermittent claudication Yes 73 (56.6) < 0.001
No/other leg pain 284 (23.5)
Pulseless dorsalis pedis/posterior tibial artery Yes 164 (51.1) < 0.001
No 188 (19.1)
At least one Yes 243 (41.5) < 0.001
No 102 (16.2)
Modiﬁable cardiovascular risk factors
Hypertension Yes 295 (28.9) < 0.001
No 62 (19.4)
Hypercholesterolaemia Yes 278 (27.2) 0.428
No 79 (24.9)
Smoking Current/cessation ≤ 1 year 77 (36.8) < 0.001
No/cessation > 1 year 280 (24.8)
Diabetes Yes 147 (34.7) < 0.001
No 210 (22.9)
Number of risk factors 4 19 (39.6) < 0.001
3 128 (37.6)
2 139 (23.5)
1 59 (20.8)
0 12 (15.4)
Measurements at the visit
Systolic blood pressure (mmHg) < 140 133 (21.5) < 0.001
140—< 160 163 (30.0)
≥ 160 61 (34.5)
Low-density lipoprotein cholesterol (mmol/L) < 2.6 82 (24.4) 0.005
2.6—< 3.3 72 (22.0)
3.3—< 4 76 (34.2)
≥ 4 43 (31.9)
High-density lipoprotein cholesterol (mmol/L) < 1 45 (30.8) 0.364
1—< 1.5 148 (26.4)
≥ 1.5 73 (24.5)
Cardiovascular history
Angina pectoris Yes 280 (28.1) 0.042
No 77 (22.4)
Myocardial infarction Yes 149 (25.9) 0.211
No 208 (28.0)
Coronary artery bypass graft or angioplasty Yes 169 (25.1) 0.192
No 188 (28.2)
Abdominal aortic aneurysm Yes 6 (16.2) 0.146
Prevalence of unknown PAD in CAD patients 629
Table 2 (Continued )
Patient characteristic Prevalence of PAD, n (%) p
No 351 (26.9)
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Outcome measure
The primary outcome was the prevalence of PAD, deﬁned
as ABI less than 0.90 [16]. ABI provides objective data
easily and is now the recommended standard for diagnos-
ing PAD [4]. Blood pressure measurements were performed
under standardized conditions by the general practition-
ers. A Doppler ultrasonic pen device (8mHz, Mini Dopplex®
D900/EZ8, Huntleigh Healthcare Inc., Eatontown, NJ, USA)
was used with a standard sphygmomanometer at each site.
We chose the most sensitive method for calculating ABI, i.e.
division of the lowest of the four ankle systolic pressures
(posterior tibial and dorsalis pedis arteries) by the brachial
systolic pressure [17].
Statistical analysis
Standard descriptive statistics were provided for all
variables; 95% CIs were calculated when appropriate. Pro-
portions were calculated taking into account missing data in
the denominator. Groups were compared using the chi2 test.
Factors predictive of PAD were investigated by multivariable
logistic regression with stepwise backward procedure (at the
0.20 level), regardless of the univariate analyses results. The
following variables were entered into the initial model:
• patients’ characteristics (age and signs or symptoms sug-
gestive of PAD);
• cardiovascular risk factors (hypertension, hypercholes-
terolaemia, diabetes, smoking status, brachial SBP at the
visit and latest measurement of LDL cholesterol);
T
C
w
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Table 3 Independent predictors of peripheral arterial diseas
logistic regression.
Variable Reference
Age ≥ 74 years vs 55—63 years
Age 64—73 years vs 55—63 years
Intermittent claudication vs absent
Other leg pain while walking vs absent
Pulseless dorsalis pedis artery vs absent
Pulseless tibial artery vs absent
History of hypertension and latest SBP
≥ 140mmHg
vs no history and
No history of hypercholesterolaemia but
latest LDL ≥ 3.3mmol/L
vs no history and
Smoking (current) vs no
Smoking (cessation ≤ 1 year) vs no
Smoking (cessation > 1 year) vs no
Diabetes vs no
LDL: low-density lipoprotein; SBP: systolic blood pressure; CI: conﬁdenabdominal aortic aneurysm.
The corresponding odds ratios and their 95% CIs were
alculated. Statistical signiﬁcance was accepted at the two-
ided 0.05 level. Data were analysed using SAS® 8.02 (SAS
nstitute Inc., Cary, NC, USA).
esults
atient characteristics
etween 2nd May 2005 and 15th February 2006, 1219 gen-
ral practitioners throughout France enrolled 5679 high-risk
atients aged 55 years or over in the IPSILON study. His-
ory of atherothrombotic events was recorded in 2393
atients; of these, 1340 (56.0%) patients had isolated CAD,
64 (15.2%) had CAD plus cerebrovascular disease and/or
known history of PAD and 689 (28.8%) had no history
f CAD. PAD was already known in 79 patients with CAD.
able 1 summarizes the main characteristics of the 1340
atients with isolated CAD, who comprise the study pop-
lation.
revalence of unknown PAD in CAD patients
univariate analyses)he prevalence of unknown PAD in patients with isolated
AD was 26.6% (n = 357; 95% CI 24.3—29.1). Severity of PAD
as moderate in most patients, with an ABI less than 0.5 in
hree (0.8%) cases only, between 0.5 and less than 0.75 in
e in patients with coronary artery disease: multivariable
Odds ratio (95% CI) p
1.88 (1.28—2.76) 0.001
1.40 (0.95—2.05) 0.087
2.98 (1.93—4.59) < 0.001
1.91 (1.38—2.63) < 0.001
3.11 (2.21—4.39) < 0.001
1.62 (1.08—2.43) 0.020
latest SBP < 140mmHg 1.55 (1.02—2.35) 0.040
latest LDL < 3.3mmol/L 2.90 (1.31—6.43) 0.009
1.82 (1.16—2.87) 0.010
2.96 (1.62—5.40) < 0.001
1.56 (1.14—2.13) 0.005
1.51 (1.14—2.02) 0.005
ce interval.
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(Winner Pharma, France) helped with ﬁeld monitoring. F.30
38 (38.7%) cases and between 0.75 and less than 0.9 in 216
60.5%) cases.
Univariate analyses in the 357 patients with CAD and
AD (Table 2) showed an increased prevalence of unknown
AD with older age, higher number of cardiovascular risk
actors, higher SBP at the visit and increased LDL choles-
erol at the latest measurement. In patients with signs or
ymptoms suggestive of PAD, PAD was found in 43.2%, which
as approximately twice as frequent as in asymptomatic
atients. The prevalence of PAD was also higher in patients
ith hypertension, diabetes and angina pectoris, and in
mokers (or patients who had stopped smoking in the past
ear).
actors associated with PAD in CAD patients
multivariate analyses)
he independent variables signiﬁcantly associated with the
iagnosis of PAD in patients with isolated CAD are displayed
n Table 3. The statistical model retained the following vari-
bles as risk factors for PAD:
older age;
any symptom suggestive of PAD;
cardiovascular risk factors (smoking, diabetes, uncon-
trolled arterial hypertension and elevated LDL choles-
terol).
iscussion
n the primary care setting, ABI measurement enabled the
etection of PAD in 26.6% of 1340 patients with CAD and no
ther known location of atherothrombotic disease; 16.2% of
AD patients presented with asymptomatic PAD. Prevalence
f unknown PAD was increased signiﬁcantly in patients with
iabetes mellitus, whereas myocardial infarction and coro-
ary surgery or angioplasty was not associated with a higher
ate of PAD. Independent factors predictive of PAD were
dentiﬁed, such as older age and current or former smoking.
Our study has an observational design, without any study-
peciﬁc intervention apart from ABI measurement. The data
rovide a unique, up-to-date picture of PAD screening among
AD patients in France. A weakness may be the subgroup
nalysis, which resulted in the statistical analysis being less
owerful and a lack of certain information that would have
een of interest in the context of CAD. To our knowledge,
owever, little recent information on PAD in CAD patients is
vailable, especially on unknown PAD.
The overall prevalence of PAD was 27.8% in the whole
PSILON cohort. Prevalence of PAD ranged from 10.4% in
atients with a high-risk cardiovascular proﬁle only to
pproximately 38% in patients with symptoms suggestive
f PAD [15]. We found here a high prevalence (26.6%) of
nknown PAD in CAD patients. This is in line with previ-
us estimations where ABI measurement was used (30—40%)
11,18,19] and, as expected, is higher than estimations
ased on clinical ﬁndings only (< 10%) [14,20,21]. Further-
ore, 16.2% of our CAD patients (i.e. more than half of the
atients with CAD plus PAD) presented with asymptomatic
AD. Prevalence of PAD was increased in diabetic patients
ith CAD (34.7%) in univariate analyses. Finally, we iden-
iﬁed independent predictors of PAD in CAD patients, as
B
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ollows: older age, any symptom suggestive of PAD, smoking,
iabetes, uncontrolled arterial hypertension and elevated
DL cholesterol.
Our results conﬁrm that widespread use of ABI measure-
ent would enable the detection of a subgroup of patients at
particularly high level of risk. Indeed, an adverse one-year
utcome occurs more often in CAD patients with PAD than
n those without PAD [11,22]. We must emphasize the fact
hat, in the literature, PAD in CAD patients is associated with
n increased severity of the disease at the different stages
f the disease course [10]. The patients have a multivessel
isease more frequently, they experience more events after
cute coronary syndrome [23] but also in cases of stable
ngina, and they have a higher rate of death after per-
utaneous coronary intervention and after coronary artery
ypass grafting [24]. Altogether, these results suggest that
iagnosis and control of risk factors in PAD patients need
o be improved. This subgroup of patients should achieve
ighter risk reduction and could beneﬁt from speciﬁc treat-
ent targets. For example, an LDL cholesterol goal of less
han 70mg/dL could be a therapeutic option [4].
In conclusion, unknown PAD was diagnosed by ABI mea-
urement in 26.6% of CAD patients with no other known
ocation of atherothrombotic disease, and PAD was asymp-
omatic in 16.2% of CAD patients. Screening with ABI would
llow the identiﬁcation of a subgroup of CAD patients at par-
icularly high risk and who could beneﬁt from an aggressive
edical treatment strategy. Our results should be conﬁrmed
n further studies.
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